Cargando…
Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
Cervical cancer (CC) is the fourth most common cause of cancer-related death in women. According to international guidelines, a standard treatment for locally advanced cervical cancer (LACC) consists of exclusive concurrent chemoradiation treatment (CRT). However, chemoradioresistance and subsequent...
Autores principales: | Raspaglio, Giuseppina, Buttarelli, Marianna, Filippetti, Flavia, Battaglia, Alessandra, Buzzonetti, Alexia, Scambia, Giovanni, Gallo, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511191/ https://www.ncbi.nlm.nih.gov/pubmed/34642300 http://dx.doi.org/10.1038/s41419-021-04229-y |
Ejemplares similares
-
Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023) -
A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
por: Buttarelli, Marianna, et al.
Publicado: (2019) -
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
por: Iwata, Hiroshi, et al.
Publicado: (2016) -
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017) -
Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)